Cytokine gene variation is associated with depressive symptom trajectories in oncology patients and family caregivers

Laura B. Dunn, Bradley E. Aouizerat, Dale J. Langford, Bruce A. Cooper, Anand Dhruva, Janine K. Cataldo, Christina R. Baggott, John D. Merriman, Marylin Dodd, Claudia West, Steven M. Paul, Christine Miaskowski

Research output: Contribution to journalArticle

Abstract

Purpose: Depressive symptoms are common in cancer patients and their family caregivers (FCs). While these symptoms are characterized by substantial interindividual variability, the factors that predict this variability remain largely unknown. This study sought to confirm latent classes of oncology patients and FCs with distinct depressive symptom trajectories and to examine differences in phenotypic and genotypic characteristics among these classes. Method: Among 167 oncology outpatients with breast, prostate, lung, or brain cancer and 85 of their FCs, growth mixture modeling (GMM) was used to identify latent classes of individuals based on Center for Epidemiological Studies-Depression (CES-D) scores obtained prior to, during, and for four months following completion of radiation therapy. One hundred four single nucleotide polymorphisms (SNPs) and haplotypes in 15 candidate cytokine genes were interrogated for differences between the two largest latent classes. Multivariate logistic regression analyses assessed effects of phenotypic and genotypic characteristics on class membership. Results: Four latent classes were confirmed: Resilient (56.3%), Subsyndromal (32.5%), Delayed (5.2%), and Peak (6.0%). Participants who were younger, female, non-white, and who reported higher baseline trait and state anxiety were more likely to be in the Subsyndromal, Delayed, or Peak groups. Variation in three cytokine genes (i.e., interleukin 1 receptor 2 [IL1R2], IL10, tumor necrosis factor alpha [TNFA]), age, and performance status predicted membership in the Resilient versus Subsyndromal classes. Conclusions: Findings confirm the four latent classes of depressive symptom trajectories previously identified in a sample of breast cancer patients. Variations in cytokine genes may influence variability in depressive symptom trajectories.

Original languageEnglish (US)
Pages (from-to)346-353
Number of pages8
JournalEuropean Journal of Oncology Nursing
Volume17
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Caregivers
Depression
Cytokines
Genes
Interleukin-1 Receptors
Brain Neoplasms
Interleukin-10
Haplotypes
Single Nucleotide Polymorphism
Epidemiologic Studies
Lung Neoplasms
Prostatic Neoplasms
Breast
Outpatients
Radiotherapy
Anxiety
Tumor Necrosis Factor-alpha
Logistic Models
Regression Analysis
Breast Neoplasms

Keywords

  • Cancer
  • Cytokines
  • Depression
  • Family caregivers
  • Genetics
  • Growth mixture modeling
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology(nursing)

Cite this

Cytokine gene variation is associated with depressive symptom trajectories in oncology patients and family caregivers. / Dunn, Laura B.; Aouizerat, Bradley E.; Langford, Dale J.; Cooper, Bruce A.; Dhruva, Anand; Cataldo, Janine K.; Baggott, Christina R.; Merriman, John D.; Dodd, Marylin; West, Claudia; Paul, Steven M.; Miaskowski, Christine.

In: European Journal of Oncology Nursing, Vol. 17, No. 3, 06.2013, p. 346-353.

Research output: Contribution to journalArticle

Dunn, LB, Aouizerat, BE, Langford, DJ, Cooper, BA, Dhruva, A, Cataldo, JK, Baggott, CR, Merriman, JD, Dodd, M, West, C, Paul, SM & Miaskowski, C 2013, 'Cytokine gene variation is associated with depressive symptom trajectories in oncology patients and family caregivers', European Journal of Oncology Nursing, vol. 17, no. 3, pp. 346-353. https://doi.org/10.1016/j.ejon.2012.10.004
Dunn, Laura B. ; Aouizerat, Bradley E. ; Langford, Dale J. ; Cooper, Bruce A. ; Dhruva, Anand ; Cataldo, Janine K. ; Baggott, Christina R. ; Merriman, John D. ; Dodd, Marylin ; West, Claudia ; Paul, Steven M. ; Miaskowski, Christine. / Cytokine gene variation is associated with depressive symptom trajectories in oncology patients and family caregivers. In: European Journal of Oncology Nursing. 2013 ; Vol. 17, No. 3. pp. 346-353.
@article{fdc26e4225934befa339b8bb77ac0608,
title = "Cytokine gene variation is associated with depressive symptom trajectories in oncology patients and family caregivers",
abstract = "Purpose: Depressive symptoms are common in cancer patients and their family caregivers (FCs). While these symptoms are characterized by substantial interindividual variability, the factors that predict this variability remain largely unknown. This study sought to confirm latent classes of oncology patients and FCs with distinct depressive symptom trajectories and to examine differences in phenotypic and genotypic characteristics among these classes. Method: Among 167 oncology outpatients with breast, prostate, lung, or brain cancer and 85 of their FCs, growth mixture modeling (GMM) was used to identify latent classes of individuals based on Center for Epidemiological Studies-Depression (CES-D) scores obtained prior to, during, and for four months following completion of radiation therapy. One hundred four single nucleotide polymorphisms (SNPs) and haplotypes in 15 candidate cytokine genes were interrogated for differences between the two largest latent classes. Multivariate logistic regression analyses assessed effects of phenotypic and genotypic characteristics on class membership. Results: Four latent classes were confirmed: Resilient (56.3{\%}), Subsyndromal (32.5{\%}), Delayed (5.2{\%}), and Peak (6.0{\%}). Participants who were younger, female, non-white, and who reported higher baseline trait and state anxiety were more likely to be in the Subsyndromal, Delayed, or Peak groups. Variation in three cytokine genes (i.e., interleukin 1 receptor 2 [IL1R2], IL10, tumor necrosis factor alpha [TNFA]), age, and performance status predicted membership in the Resilient versus Subsyndromal classes. Conclusions: Findings confirm the four latent classes of depressive symptom trajectories previously identified in a sample of breast cancer patients. Variations in cytokine genes may influence variability in depressive symptom trajectories.",
keywords = "Cancer, Cytokines, Depression, Family caregivers, Genetics, Growth mixture modeling, Radiation therapy",
author = "Dunn, {Laura B.} and Aouizerat, {Bradley E.} and Langford, {Dale J.} and Cooper, {Bruce A.} and Anand Dhruva and Cataldo, {Janine K.} and Baggott, {Christina R.} and Merriman, {John D.} and Marylin Dodd and Claudia West and Paul, {Steven M.} and Christine Miaskowski",
year = "2013",
month = "6",
doi = "10.1016/j.ejon.2012.10.004",
language = "English (US)",
volume = "17",
pages = "346--353",
journal = "European Journal of Oncology Nursing",
issn = "1462-3889",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Cytokine gene variation is associated with depressive symptom trajectories in oncology patients and family caregivers

AU - Dunn, Laura B.

AU - Aouizerat, Bradley E.

AU - Langford, Dale J.

AU - Cooper, Bruce A.

AU - Dhruva, Anand

AU - Cataldo, Janine K.

AU - Baggott, Christina R.

AU - Merriman, John D.

AU - Dodd, Marylin

AU - West, Claudia

AU - Paul, Steven M.

AU - Miaskowski, Christine

PY - 2013/6

Y1 - 2013/6

N2 - Purpose: Depressive symptoms are common in cancer patients and their family caregivers (FCs). While these symptoms are characterized by substantial interindividual variability, the factors that predict this variability remain largely unknown. This study sought to confirm latent classes of oncology patients and FCs with distinct depressive symptom trajectories and to examine differences in phenotypic and genotypic characteristics among these classes. Method: Among 167 oncology outpatients with breast, prostate, lung, or brain cancer and 85 of their FCs, growth mixture modeling (GMM) was used to identify latent classes of individuals based on Center for Epidemiological Studies-Depression (CES-D) scores obtained prior to, during, and for four months following completion of radiation therapy. One hundred four single nucleotide polymorphisms (SNPs) and haplotypes in 15 candidate cytokine genes were interrogated for differences between the two largest latent classes. Multivariate logistic regression analyses assessed effects of phenotypic and genotypic characteristics on class membership. Results: Four latent classes were confirmed: Resilient (56.3%), Subsyndromal (32.5%), Delayed (5.2%), and Peak (6.0%). Participants who were younger, female, non-white, and who reported higher baseline trait and state anxiety were more likely to be in the Subsyndromal, Delayed, or Peak groups. Variation in three cytokine genes (i.e., interleukin 1 receptor 2 [IL1R2], IL10, tumor necrosis factor alpha [TNFA]), age, and performance status predicted membership in the Resilient versus Subsyndromal classes. Conclusions: Findings confirm the four latent classes of depressive symptom trajectories previously identified in a sample of breast cancer patients. Variations in cytokine genes may influence variability in depressive symptom trajectories.

AB - Purpose: Depressive symptoms are common in cancer patients and their family caregivers (FCs). While these symptoms are characterized by substantial interindividual variability, the factors that predict this variability remain largely unknown. This study sought to confirm latent classes of oncology patients and FCs with distinct depressive symptom trajectories and to examine differences in phenotypic and genotypic characteristics among these classes. Method: Among 167 oncology outpatients with breast, prostate, lung, or brain cancer and 85 of their FCs, growth mixture modeling (GMM) was used to identify latent classes of individuals based on Center for Epidemiological Studies-Depression (CES-D) scores obtained prior to, during, and for four months following completion of radiation therapy. One hundred four single nucleotide polymorphisms (SNPs) and haplotypes in 15 candidate cytokine genes were interrogated for differences between the two largest latent classes. Multivariate logistic regression analyses assessed effects of phenotypic and genotypic characteristics on class membership. Results: Four latent classes were confirmed: Resilient (56.3%), Subsyndromal (32.5%), Delayed (5.2%), and Peak (6.0%). Participants who were younger, female, non-white, and who reported higher baseline trait and state anxiety were more likely to be in the Subsyndromal, Delayed, or Peak groups. Variation in three cytokine genes (i.e., interleukin 1 receptor 2 [IL1R2], IL10, tumor necrosis factor alpha [TNFA]), age, and performance status predicted membership in the Resilient versus Subsyndromal classes. Conclusions: Findings confirm the four latent classes of depressive symptom trajectories previously identified in a sample of breast cancer patients. Variations in cytokine genes may influence variability in depressive symptom trajectories.

KW - Cancer

KW - Cytokines

KW - Depression

KW - Family caregivers

KW - Genetics

KW - Growth mixture modeling

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84876314568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876314568&partnerID=8YFLogxK

U2 - 10.1016/j.ejon.2012.10.004

DO - 10.1016/j.ejon.2012.10.004

M3 - Article

VL - 17

SP - 346

EP - 353

JO - European Journal of Oncology Nursing

JF - European Journal of Oncology Nursing

SN - 1462-3889

IS - 3

ER -